| 2.22 -0.2 (-8.26%) | 07-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.29  |
1-year : | 3.76 |
| Resists | First : | 2.82 |
Second : | 3.22 |
| Pivot price | 2.64 |
|||
| Supports | First : | 2.17 |
Second : | 1.8 |
| MAs | MA(5) : | 2.42 |
MA(20) : | 2.73 |
| MA(100) : | 3.14 |
MA(250) : | 4.95 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 6.9 |
D(3) : | 9.4 |
| RSI | RSI(14): 21.1 |
|||
| 52-week | High : | 12.02 | Low : | 2.17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ACON ] has closed below the lower bollinger band by 6.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 34.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.44 - 2.46 | 2.46 - 2.48 |
| Low: | 2.13 - 2.15 | 2.15 - 2.17 |
| Close: | 2.14 - 2.17 | 2.17 - 2.2 |
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
Mon, 27 Jul 2026
Aclarion Inc (ACON) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mon, 27 Jul 2026
Aclarion Inc (ACON) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mon, 27 Jul 2026
Aclarion Inc (ACON) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mon, 27 Jul 2026
Aclarion Market Sentiment - Benzinga España
Tue, 21 Jul 2026
Aclarion Nociscan Case Reports 95% Relief Without Classic MRI Signs - Stock Titan
Thu, 25 Jun 2026
ACON Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 2.2e+006 (%) |
| Held by Institutions | 26.2 (%) |
| Shares Short | 126 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.31e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -14 % |
| Return on Assets (ttm) | 129.3 % |
| Return on Equity (ttm) | -28.8 % |
| Qtrly Rev. Growth | 77880 % |
| Gross Profit (p.s.) | 9.33 |
| Sales Per Share | -37.55 |
| EBITDA (p.s.) | 12454.5 |
| Qtrly Earnings Growth | -5.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.06 |
| Price to Cash Flow | 0.32 |
| Dividend | 0 |
| Forward Dividend | 42700 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|